Search 

A private pharmaceutical company,headquartered in Beijing,focus on the research, development,manufacture and marketing of drug products for the treatment of organ fibrosis diseases and other related diseases.

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

InorbitTX is a virtual drug discovery and development company focussed on the treatment of fatty liver diseases NAFLD / NASH. Its lead project, the FXR agonist IOT022 is currently in late pre-clinical testing. IOT022 differentiates very well from competitor compounds, as it mitigates the risk for pruritus and for drug induced liver injury, seen with competitors. It gives IOT022 an excellent best-in-class opportunity. InorbitTX second project is a KHK inhibitor, IOT038, also for the treatment of NAFLD / NASH.IOT038 shows excellent astute efficacy in animals We look for funding to complete for IND and for Phase I. We also look for partnering for the Chinese / Asian market.